English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background To address the United States Food &amp; Drug Administration’s recent safety concern on robotic surgery procedures, we compared short- and long-term mortality for stage I non-small cell lung cancer (NSCLC) patients treated by robotic-assisted thoracoscopic surgical lobectomy (RATS-L) versus video-assisted thoracoscopic surgical lobectomy (VATS-L). Methods From the National Cancer Database, we identified 18,908 stage I NSCLC patients who underwent RATS-L or VATS-L as the primary operation from 2010 to 2014. Cox proportional hazards models were used to estimate hazard ratios (HRs) for short- and long-term mortality using unmatched and propensity score-matched analyses. All statistical tests were two-sided. Results Patients treated by RATS-L had higher 90-day mortality than those with VATS-L (6.6% vs. 3.8%; P=.03) if conversion to open thoracotomy occurred. After excluding first-year observation, multiple regression analyses showed RATS-L was associated with increased long-term mortality, compared to VATS-L, in cases with tumor size ≤20 mm: HRs were 1.33 (95%CI: 1.15-1.55), 1.36 (95%CI: 1.17-1.58) and 1.33 (95%CI: 1.11-1.61) for unmatched, N:1 matched and 1:1 matched analyses, respectively, in the intention-to-treat analysis. Among patients without conversion to an open thoracotomy, the respective HRs were 1.19 (95%CI: 1.10-1.29), 1.19 (95%CI: 1.10-1.29) and 1.17 (95%CI: 1.06-1.29). Similar associations were observed when follow-up time started 18- or 24-months post-surgery. No statistically significant mortality difference was found for patients with tumor size &amp;gt;20 mm. These associations were not related to case volume of VATS-L/RATS-L performed at treatment institutes. Conclusions Patients with small (≤20 mm) stage I NSCLC treated with RATS-L had statistically significantly higher long-term mortality risk than VATS-L after one-year post-surgery.

Mortality for robotic- versus video-assisted lobectomy treated stage I non-small cell lung cancer patients